lobbying_activities: 1238268

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1238268 1eacfb18-0093-4782-8ed9-783a1a334e39 Q1 NOSSAMAN LLP 29846 AMERISOURCEBERGEN CORPORATION (FORMERLY "AMERISOURCEBERGEN SPECIALTY GROUP") 2012 first_quarter PHA H.R.905 and S.733, legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1483, H.R.3026 and S.1584, pharmaceutical pedigree anti-counterfeiting legislation. H.R.2245 and S.296, legislation pertaining to drug manufacturing shortages. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2012-04-19T15:10:55.953000-04:00